BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29536433)

  • 1. Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS).
    Rochira V; Mossetto G; Jia N; Cannavo S; Beck-Peccoz P; Aimaretti G; Ambrosio MR; Di Somma C; Losa M; Ferone D; Lubrano C; Scaroni C; Giampietro A; Corsello SM; Poggi M
    J Endocrinol Invest; 2018 Nov; 41(11):1259-1266. PubMed ID: 29536433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database.
    Abs R; Mattsson AF; Bengtsson BA; Feldt-Rasmussen U; Góth MI; Koltowska-Häggström M; Monson JP; Verhelst J; Wilton P;
    Growth Horm IGF Res; 2005 Oct; 15(5):349-59. PubMed ID: 16168692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry.
    Losa M; Beck-Peccoz P; Aimaretti G; Di Somma C; Ambrosio MR; Ferone D; Giampietro A; Corsello SM; Poggi M; Scaroni C; Jia N; Mossetto G; Cannavò S; Rochira V
    Clin Endocrinol (Oxf); 2015 Oct; 83(4):527-35. PubMed ID: 26119712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency.
    Franco C; Johannsson G; Bengtsson BA; Svensson J
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4408-14. PubMed ID: 16940452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A therapeutic trial of growth hormone in hypopituitary adults and its influence upon continued prescription by general practitioners.
    Davies JS; Obuobie K; Smith J; Rees DA; Furlong A; Davies N; Evans LM; Scanlon MF
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):295-303. PubMed ID: 10718827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influences on quality of life in GH deficient adults and their effect on response to treatment.
    Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Smethurst LE; Shalet SM
    Clin Endocrinol (Oxf); 1999 Nov; 51(5):565-73. PubMed ID: 10594517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy.
    Monson JP; Jönsson P; Koltowska-Häggström M; Kourides I
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):623-8. PubMed ID: 17581260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables.
    Abrams P; Boquete H; Fideleff H; Feldt-Rasmussen U; Jönsson PJ; Koltowska-Häggström M; Wilton P; Abs R
    Eur J Endocrinol; 2008 Dec; 159(6):825-32. PubMed ID: 18713841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F; Unluhizarci K; Kula M; Guven M; Bayram F; Kelestimur F
    Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
    Abs R; Feldt-Rasmussen U; Mattsson AF; Monson JP; Bengtsson BA; Góth MI; Wilton P; Koltowska-Häggström M
    Eur J Endocrinol; 2006 Jul; 155(1):79-90. PubMed ID: 16793953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
    Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
    Bengtsson BA; Abs R; Bennmarker H; Monson JP; Feldt-Rasmussen U; Hernberg-Stahl E; Westberg B; Wilton P; Wüster C
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency.
    Götherström G; Bengtsson BA; Bosaeus I; Johannsson G; Svensson J
    Eur J Endocrinol; 2007 Jan; 156(1):55-64. PubMed ID: 17218726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania.
    Moock J; Albrecht C; Friedrich N; Völzke H; Nauck M; Koltowska-Haggström M; Kohlmann T; Wallaschofski H
    Eur J Endocrinol; 2009 Jan; 160(1):17-24. PubMed ID: 18974232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy.
    Hayes FJ; Fiad TM; McKenna TJ
    Metabolism; 1999 Mar; 48(3):308-13. PubMed ID: 10094105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak.
    Feldt-Rasmussen U; Brabant G; Maiter D; Jonsson B; Toogood A; Koltowska-Haggstrom M; Rasmussen AK; Buchfelder M; Saller B; Biller BM
    Eur J Endocrinol; 2013 May; 168(5):733-43. PubMed ID: 23416951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult GH deficiency in Japanese patients: effects of GH treatment in a randomised, placebo-controlled trial.
    Chihara K; Koledova E; Shimatsu A; Kato Y; Kohno H; Tanaka T; Teramoto A; Bates PC; Attanasio AF
    Eur J Endocrinol; 2004 Sep; 151(3):343-50. PubMed ID: 15362963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fifteen years of GH replacement improves body composition and cardiovascular risk factors.
    Elbornsson M; Götherström G; Bosæus I; Bengtsson BÅ; Johannsson G; Svensson J
    Eur J Endocrinol; 2013 May; 168(5):745-53. PubMed ID: 23428613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.